Development and evaluation of a CRISPR/Cas12a-based diagnostic test for rapid detection and genotyping of HR-HPV in clinical specimens
Microbiology Spectrum · 2025
DOI: 10.1128/spectrum.02253-24 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Lijuan Yin und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Industrial Microbiology, Ministry of Education, Tianjin Key Laboratory of Indust…. Hauptthemen laut MEDLINE: Papillomavirus Infections, CRISPR-Cas Systems, Sensitivity and Specificity, Genotype. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Science and Technology Plan (in the field of Medical and health care) of Xiangyang, Tianjin Science and technology planning project.
Abstract (Originalsprache)
Persistent infection with high-risk human papillomavirus (HR-HPV) is the principal etiological factor of cervical cancer. Considering the gradual progression of cervical cancer, the early, rapid, sensitive, and specific identification of HPV, particularly HR-HPV types, is crucial in halting the advancement of the illness. Here, we established a rapid, highly sensitive, and specific HR-HPV detection platform, leveraging the CRISPR/Cas12a assay in conjunction with multienzyme isothermal rapid amplification. Our platform enables the detection and genotyping of 14 types of HR-HPV by using type-specific crRNAs. The outcomes of the detection can be interpreted either through a fluorescence reader or visually. Furthermore, we achieved one-tube multiplex detection of 14 HR-HPV types through the use of multiple amplifications and a crRNA pool. The detection sensitivity of this method is 2 copies/μL with no cross-reactivity, and the results can be obtained within 30 minutes. This method exhibited 100% clinical sensitivity and 100% clinical specificity when applied to 258 clinical specimens. Based on these findings, our CRISPR/Cas-based HR-HPV detection platform holds promise as a novel clinical detection tool, offering a visually intuitive and expedited alternative to existing HPV infection diagnostics and providing fresh perspectives for clinical cervical cancer screening. IMPORTANCE This study developed a novel high-risk human papillomavirus (HR-HPV) detection platform based on CRISPR/Cas12a technology. This platform not only enables the rapid, highly sensitive, and specific detection and genotyping of 14 types of HR-HPV but also achieves single-tube multiplex detection of 14 HR-HPV types through ingenious design. The outcomes of the detection can be interpreted either through a fluorescence reader or visually. To the best of our knowledge, this is the first paper to utilize CRISPR/Cas diagnostic technology for the simultaneous detection of 14 types of HPV and to evaluate its feasibility in clinical sample detection using a large number of clinical samples. We hope that this work will facilitate the rapid and accurate detection of HPV and promote the broader application of CRISPR/Cas diagnostic technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Industrial Microbiology, Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, National and Local United Engineering Lab of Metaboli…
- Department of Clinical Laboratory, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China.
- Department of Clinical Laboratory, Xiangyang No.1 People's Hospital, Hubei Universitly of Medicine, Xiangyang, China.
- Dynamiker Sub-Center of Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Disease, Tianjin, China.
- Academy of National Food and Strategic Reserves Administration, Beijing, China.
- Institute of Pediatrics, Faculty of Pediatrics, The Seventh Medical Center of Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Lijuan Yin, Shuli Man, Xinkuan Cheng, Siqi Hu, Hongxia Fan, Long Ma, Hui Xing, Liang Shen
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- Science and Technology Plan (in the field of Medical and health care) of Xiangyang
- Tianjin Science and technology planning project
- Tianjin Municipal Science and Technology Committee (Tianjin Municipal Science and Technology Commission)
- China Postdoctoral Science Foundation (China Postdoctoral Foundation Project)
- Liquor Making Biological Technology and Application of Key Laboratory of Sichuan Province Microbiology
- General Project of Natural Science Foundation of Hubei Province
- Young and middle-aged Talents Project of Hubei Provincial Education Department
Zitieren
APA
Yin, L., Zhao, Z., Wang, C., Zhou, C., Wu, X., Gao, B., Wang, L., Man, S., Cheng, X., Wu, Q., Hu, S., Fan, H., Ma, L., Xing, H., & Shen, L. (2025). Development and evaluation of a CRISPR/Cas12a-based diagnostic test for rapid detection and genotyping of HR-HPV in clinical specimens. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02253-24
Vancouver
Yin L, Zhao Z, Wang C, Zhou C, Wu X, Gao B, et al. Development and evaluation of a CRISPR/Cas12a-based diagnostic test for rapid detection and genotyping of HR-HPV in clinical specimens. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02253-24
BibTeX
@article{Yin2025,
author = {Yin, Lijuan and Zhao, Ziqian and Wang, Chunhua and Zhou, Caihong and Wu, Xiuzhen and Gao, Baoxue and Wang, Liangyuan and Man, Shuli and Cheng, Xinkuan and Wu, Qiankun and Hu, Siqi and Fan, Hongxia and Ma, Long and Xing, Hui and Shen, Liang},
title = {Development and evaluation of a CRISPR/Cas12a-based diagnostic test for rapid detection and genotyping of HR-HPV in clinical specimens},
journal = {Microbiology Spectrum},
year = {2025},
doi = {10.1128/spectrum.02253-24}
}
EUVIMED